GSK
1,795.00 GBpChange from previous close: −2.02%Absolute change: −37.00 GBp
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- £71.9B
- Enterprise value
- £88.13B
- P/E (trailing 12 months)
- 15.2
- Forward P/E
- 9.41
- PEG
- 5.98
- Price/book
- 407.6
- Price/sales
- 2.17
- EV/EBITDA
- 8.15
- EV/revenue
- 2.65
Profitability and growth
- Gross margin
- 73.5%
- Operating margin
- 30.9%
- Net margin
- 14.5%
- ROE
- 33.4%
- ROA
- 10.0%
- Revenue growth (year over year)
- 5.3%
- Earnings growth (year over year)
- -69.5%
Financial health
- Total cash
- £3.11B
- Total debt
- £18.29B
- Debt/equity
- 1.06
- Current ratio
- 0.82
- Quick ratio
- 0.52
Dividends
- Annual dividend per share
- 0.68 GBp
- Dividend yield
- 3.7%
- Payout ratio
- 56.9%
- Ex-dividend date
- August 13, 2026
Analysts and estimates
- Average price target
- 2,174.81 GBp
- Median price target
- 2,100.00 GBp
- High price target
- 3,010.00 GBp
- Low price target
- 1,455.00 GBp
- Analysts with a price target
- 21
- Consensus
- Hold
- Forward EPS
- 1.91 GBp
- EPS estimate, current year
- 1.79 GBp
Shares and trading
- Beta
- 0.29
- Average volume
- 6.85M
- Shares outstanding
- 4.01B
- Float
- 3.88B
- Institutional ownership
- 49.1%
- Insider ownership
- 1.7%